Tardive Dyskinesia Treatment | AUSTEDO XR® (deutetrabenazine)
The most common side effects of AUSTEDO in people with tardive dyskinesia include inflammation of the nose and throat (nasopharyngitis) and problems sleeping (insomnia). These are not all the …
Tardive Dyskinesia (TD) Treatment Guidelines
The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. Adverse reactions …
What is the FDA-Approved Treatment for Tardive Dyskinesia?
Nov 26, 2025 · Learn about the FDA-approved treatment for tardive dyskinesia, specifically the VMAT2 inhibitors valbenazine (Ingrezza) and deutetrabenazine (Austedo).
Deutetrabenazine Tablets Improve Tardive Dyskinesia Symptoms
Oct 22, 2025 · Teva Pharmaceuticals announced new data from the ongoing, real-world IMPACT-TD Registry, which demonstrates that treatment with deutetrabenazine tablets or deutetrabenazine …
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR ...
6 days ago · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia.
Austedo (deutetrabenazine): Uses, Side Effects, Dosage Guide
Aug 20, 2025 · Austedo is used to treat the involuntary movements of Huntington's disease and tardive dyskinesia (TD). Includes Austedo side effects, dosage, uses, interactions, and more
Treatments – National Organization for Tardive Dyskinesia
VMAT2 inhibitors: There are two FDA-approved drugs to treat tardive dyskinesia, Ingrezza (valbenazine) and Austedo (deutetrabenazine). These medications were approved in 2017 and are known as …
How to Tell If a Tardive Dyskinesia Treatment Plan Is Working
Dec 1, 2025 · Treating tardive dyskinesia The most common option for treating TD is a vesicular monoamine transporter (VMAT2) inhibitor. The two FDA-approved options are valbenazine …
Austedo XR Approved: A New Treatment Option for Tardive Dyskinesia …
May 30, 2024 · The FDA has approved Austedo XR as a once-daily pill treatment option for tardive dyskinesia and Huntington disease chorea control.
Austedo XR: FDA Approved for tardive Dyskinesia
Jun 1, 2024 · In a significant advancement for those suffering from tardive dyskinesia (TD), the U.S. Food and Drug Administration (FDA) recently approved Austedo XR (extended-release …